CAH Treatment: Signs of Over- or Undertreatment

Understanding the Balance in CAH Treatment

Congenital adrenal hyperplasia, commonly shortened to CAH, is a group of inherited disorders affecting the adrenal glands. Most cases are caused by 21-hydroxylase deficiency. This enzyme problem reduces the body’s ability to produce cortisol and, in classic salt-wasting CAH, aldosterone. At the same time, hormone-building materials are redirected toward androgen production.

People with classic CAH generally need lifelong glucocorticoid replacement. Hydrocortisone is commonly used in growing children, while adults may use hydrocortisone or another glucocorticoid selected by their endocrinologist. Fludrocortisone is used when aldosterone replacement is needed, and infants may also require prescribed salt supplementation. Some people with nonclassic CAH need treatment for significant symptoms, while asymptomatic individuals often do not require daily glucocorticoids.

The Main Goals of Therapy

• Replace the cortisol the body cannot make adequately.
• Prevent adrenal crisis during illness, injury, surgery, or severe physical stress.
• Control excess adrenal androgen production without completely shutting down normal adrenal activity.
• Replace aldosterone and sodium when medically necessary.
• Support healthy growth, puberty, menstrual function, fertility, blood pressure, and bone health.
• Minimize long-term complications from excessive steroid exposure.

These goals explain why CAH treatment cannot be managed using a laboratory result alone. Symptoms, growth patterns, blood pressure, medication timing, puberty, menstrual history, fertility goals, and biochemical measurements must be considered together.

What Does Undertreatment of CAH Mean?

Undertreatment occurs when the body is not receiving enough glucocorticoid or mineralocorticoid for its current needs. This may happen because a maintenance dose has become inadequate, doses are missed, medication is not absorbed because of vomiting, or the dose is not increased according to the patient’s sick-day plan during significant illness or physical stress.

It can also occur when a child grows and the old dose no longer provides appropriate coverage. Medication requirements are not carved into stone tablets. They change with body size, age, health, pregnancy, surgery, and other circumstances.

Signs of Inadequate Cortisol Replacement

Possible symptoms of insufficient glucocorticoid coverage include:

• Persistent or unexplained fatigue
• Muscle weakness or reduced stamina
• Poor appetite or unintended weight loss
• Nausea, vomiting, or abdominal pain
• Dizziness, especially when standing
• Low blood pressure
• Low blood sugar, shakiness, sweating, or unusual sleepiness
• Increasing skin darkening or hyperpigmentation
• Difficulty recovering from infections or physical stress

These symptoms are not specific to CAH. Fatigue, for example, has an impressive résumé and appears in everything from anemia to an unfortunate bedtime routine. Repeated symptoms or a clear change from the person’s baseline should still be discussed with the endocrinology team.

Signs of Excess Androgen Activity

When glucocorticoid therapy does not adequately control adrenal stimulation, androgen production may increase. The signs differ according to age, sex, and developmental stage.

In children, possible signs include:

• Faster-than-expected height growth over a short period
• Advanced bone age
• Early pubic or underarm hair
• Adult-type body odor at an unusually young age
• Acne or oily skin
• Early enlargement of genital tissue
• Other signs of premature puberty or virilization

A child with androgen excess may initially appear impressively tall. Unfortunately, rapid bone maturation can cause growth plates to close early, resulting in a shorter adult height. The early growth spurt can therefore be less of a height jackpot and more of an advance payment.

In adolescents and adults, signs may include:

• Worsening acne
• Increased facial or body hair
• Scalp hair thinning
• Irregular or absent menstrual periods
• Difficulty becoming pregnant
• Deepening of the voice or other progressive virilization
• Reduced testicular function or fertility problems in males

Males with classic CAH may develop testicular adrenal rest tumors, often called TARTs. These benign masses can interfere with normal testicular tissue and fertility. Periodic testicular ultrasound beginning around adolescence may be recommended as part of long-term monitoring.

Signs of Insufficient Mineralocorticoid Replacement

People with salt-wasting CAH may also be undertreated with fludrocortisone or sodium. Possible signs include:

• Salt craving
• Dehydration
• Low blood pressure or dizziness
• Poor weight gain in an infant
• Weakness, nausea, or vomiting
• Elevated plasma renin on laboratory testing
• Low sodium or elevated potassium in more serious cases

Adrenal Crisis: When Undertreatment Becomes an Emergency

Adrenal crisis is the most dangerous consequence of inadequate cortisol availability. It can develop during a severe infection, repeated vomiting, major injury, surgery, or another significant physical stressor. It may also occur after missed medication or when oral medication cannot remain in the stomach.

Emergency Warning Signs

• Repeated vomiting or severe diarrhea
• Profound weakness or inability to stand
• Severe abdominal pain
• Confusion, unusual drowsiness, or loss of consciousness
• Fainting or very low blood pressure
• Severe dehydration
• Low blood sugar, especially in a child
• Rapid worsening during an illness

Adrenal crisis requires immediate emergency treatment. A person with CAH should follow the individualized emergency plan provided by the endocrinology team, use prescribed emergency injectable hydrocortisone when indicated, and seek emergency medical care. Oral medication should not be considered reliable when vomiting prevents absorption. People with classic CAH are also commonly advised to carry medical identification and keep emergency medication readily available.

What Does Overtreatment of CAH Mean?

Overtreatment occurs when glucocorticoid exposure is consistently higher than the body needs. A temporarily increased stress dose during a serious illness is not the same as chronic overtreatment. Stress dosing is intended to imitate the extra cortisol a healthy body would produce under major physical stress.

The concern is prolonged exposure to an excessive maintenance dose, particularly with potent or long-acting glucocorticoids. The effects may develop gradually, so trends are often more informative than a single symptom.

Signs of Excess Glucocorticoid Treatment

• Rapid or unexplained weight gain
• Increased appetite
• Slower height growth in a child
• Rounder facial appearance
• Increasing fat around the abdomen, upper back, or neck
• Thin skin, easy bruising, or wide stretch marks
• Muscle weakness
• High blood pressure
• Elevated blood sugar or insulin resistance
• Mood changes, irritability, anxiety, or sleep disturbance
• Reduced bone density or fractures after minor injuries
• More frequent infections or slower wound healing

In children, the combination of slowing height velocity and accelerating weight gain is especially important. Weight alone is not enough to diagnose excessive treatment, but weight rising while linear growth stalls deserves prompt evaluation.

Long-term excessive glucocorticoid exposure can contribute to obesity, metabolic complications, Cushingoid features, impaired growth, and reduced bone strength. Endocrine Society guidance therefore recommends monitoring for both glucocorticoid excess and inadequate androgen control rather than solving one problem by creating the other.

Signs of Excess Mineralocorticoid Treatment

Too much fludrocortisone may lead to:

• High blood pressure
• Fluid retention or swelling
• Headaches associated with rising blood pressure
• Low potassium
• Suppressed plasma renin activity

Fludrocortisone needs can change during infancy because the kidneys mature and become more responsive to mineralocorticoids. Blood pressure, electrolytes, and renin measurements help clinicians decide whether the dose remains appropriate.

Overtreatment vs. Undertreatment at a Glance

No row in this table is a do-it-yourself dose-adjustment instruction. Similar symptoms can result from other medical conditions, and abrupt changes to glucocorticoids can be dangerous.

How Doctors Determine Whether CAH Treatment Is Appropriate

Effective CAH monitoring combines clinical observations with laboratory testing. The interpretation is more like assembling a puzzle than checking whether one number has entered a green box.

Clinical Monitoring

Appointments may include evaluation of:

• Height, weight, body mass index, and growth velocity
• Blood pressure
• Pubertal development and signs of androgen excess
• Menstrual regularity and fertility goals
• Medication adherence and exact dosing schedule
• Recent illnesses, stress dosing, and adrenal emergencies
• Skin changes, bruising, muscle strength, and Cushingoid features
• Bone age when clinically appropriate
• Bone density in selected adults with prolonged high-dose exposure or fractures

Laboratory Monitoring

Depending on the patient’s age and form of CAH, clinicians may assess 17-hydroxyprogesterone, androstenedione, testosterone, sodium, potassium, and plasma renin. Reproductive hormones or fertility testing may be added when indicated.

The timing of blood collection matters because adrenal hormones vary throughout the day and change after a glucocorticoid dose. Tests should therefore be collected at a consistent time relative to medication whenever possible.

One particularly important point is that complete normalization or suppression of 17-hydroxyprogesterone is generally not the goal in classic CAH. Forcing that result may require excessive glucocorticoid exposure. Acceptable control may include mildly elevated values when growth, blood pressure, androgen levels, symptoms, and overall health are appropriate. A single unusual result should be interpreted in context rather than treated like a fire alarm with only one button.

Common Reasons a Previously Effective Dose Stops Working

• A child has gained height or weight and needs reassessment.
• Medication doses are being missed or taken at inconsistent times.
• Vomiting, diarrhea, or intestinal illness reduces absorption.
• A new medication changes glucocorticoid metabolism.
• The wrong concentration or measuring device is used for a liquid medicine.
• Stress dosing was not started during a qualifying illness.
• Fludrocortisone requirements changed as an infant’s kidneys matured.
• Pregnancy, surgery, or another major health change altered hormone needs.
• The treatment schedule does not adequately cover overnight androgen production.

Before increasing a dose, clinicians often confirm how the medication is being taken. A perfect prescription cannot perform its job while hiding at the bottom of a backpack.

Newer Treatment Options Do Not Eliminate the Need for Cortisol

Crinecerfont, marketed in the United States as Crenessity, was approved by the FDA in December 2024 as an adjunctive treatment for classic CAH in adults and children age 4 and older. It reduces the hormonal signal that drives excess adrenal androgen production and may allow some patients to control androgens with more physiologic glucocorticoid exposure.

However, crinecerfont does not replace essential glucocorticoid therapy. Patients must continue prescribed cortisol replacement and follow their emergency stress-dosing plan. Any reduction in glucocorticoid dosage should occur under specialist supervision.

What Patients and Families Can Track at Home

A simple record can help identify patterns that are difficult to remember during an appointment. Useful details include:

• Medication name, dose, and time taken
• Missed doses or doses lost through vomiting
• Illnesses and stress doses administered
• Home blood pressure readings when recommended
• Changes in weight, appetite, energy, acne, or body hair
• Menstrual dates and irregular bleeding
• Episodes of dizziness, fainting, salt craving, or low blood sugar
• Use and replacement dates of emergency hydrocortisone supplies

Patients should know where their emergency injection is stored and how to use it. Parents, partners, teachers, coaches, and caregivers may also need training. During a crisis, the emergency kit should not become the household’s most challenging escape-room puzzle.

Experiences and Practical Lessons From Everyday CAH Management

The following scenarios are educational composites based on common clinical patterns. They do not describe specific individuals and should not replace personalized medical advice.

Experience 1: The Child Who Suddenly Grew Faster

A school-age child with classic CAH had been stable for more than a year. Over several months, the family noticed a rapid increase in height, stronger body odor, oily skin, and new pubic hair. Because the child looked energetic and was getting taller, the changes did not initially seem alarming.

At the next endocrinology appointment, the growth chart showed a sharp increase in height velocity. Laboratory testing performed at the correct time relative to medication also showed increasing androgen markers. A bone-age study suggested that skeletal maturation was moving ahead too quickly.

The lesson was that rapid growth does not always mean treatment is working beautifully. In children with CAH, it can be an early sign of androgen excess and undertreatment. The care team reviewed the medication schedule, confirmed that several afternoon doses had been missed, and created a routine that fit the family’s school-day schedule. Follow-up focused on trends rather than expecting instant perfection from one adjustment.

Experience 2: Weight Gain Was Not the Only Clue

An adolescent’s family became concerned about gradual weight gain. Weight change alone could have reflected diet, activity, puberty, sleep, or dozens of other factors. The more meaningful clue appeared on the growth chart: weight was rising while height velocity had slowed noticeably.

The adolescent also reported increased appetite, difficulty sleeping, and easy bruising. Blood pressure was higher than at previous visits. Laboratory values showed strong suppression of adrenal hormone production, but those “excellent-looking” numbers did not match the clinical picture.

The endocrinologist carefully reduced glucocorticoid exposure and arranged follow-up testing using the same medication-to-blood-draw timing. The treatment goal was not to allow uncontrolled androgen excess. It was to find the lowest effective regimen that supported health without producing chronic steroid side effects.

This experience illustrates why a perfectly normal 17-hydroxyprogesterone result may not deserve a trophy. In classic CAH, complete suppression can indicate that the medication dose is unnecessarily high.

Experience 3: A Stomach Virus Became an Emergency

An adult with classic CAH developed a stomach virus and could not keep oral hydrocortisone down. At first, the person continued swallowing replacement tablets after each vomiting episode, hoping one would eventually remain in place. Weakness and dizziness increased, and standing became difficult.

A family member recognized the emergency signs, administered the prescribed hydrocortisone injection, and called emergency services. Hospital treatment included intravenous fluids, glucocorticoids, glucose monitoring, and electrolyte assessment.

The important lesson was not that the daily maintenance prescription had been wrong. The problem was that illness had increased cortisol needs while vomiting prevented medication absorption. After recovery, the family reviewed the written sick-day plan, practiced using a training device, checked the emergency medication’s expiration date, and placed kits in predictable locations.

Experience 4: The Laboratory Result That Changed With Timing

An adult received very different 17-hydroxyprogesterone and androstenedione results from two blood draws. One sample had been collected before the morning glucocorticoid dose, while the other was taken several hours afterward. Comparing the results directly created the impression that control had changed dramatically.

The endocrinology team repeated testing using consistent timing and reviewed symptoms, blood pressure, menstrual history, and medication adherence. The repeated pattern was far more useful than either isolated number.

This situation demonstrates a practical truth: laboratory values cannot explain the treatment story without knowing when the medication was taken. Consistency turns a random snapshot into a meaningful comparison.

Experience 5: The Fludrocortisone Dose That Needed Reassessment

An infant with salt-wasting CAH initially required fludrocortisone and prescribed sodium supplementation. As the baby grew, blood pressure began trending upward even though the family was following the plan precisely. Renin measurements were becoming suppressed, suggesting that mineralocorticoid exposure was now higher than necessary.

The care team adjusted treatment and continued close monitoring. No one had made an error. The infant’s kidneys had matured, changing the response to the same medication. This is why frequent pediatric follow-up is not bureaucratic enthusiasm; it is a safety tool for a rapidly changing body.

When to Contact the Endocrinology Team

Contact the treating clinician promptly for new androgen-related symptoms, repeated dizziness, unexplained weight changes, slowed childhood growth, rising blood pressure, menstrual disruption, fertility concerns, frequent illness, repeated missed doses, or uncertainty about stress dosing.

Emergency care is appropriate for severe vomiting, confusion, fainting, profound weakness, dehydration, inability to take oral medication, or other signs of adrenal crisis. Never stop glucocorticoid treatment suddenly or adjust maintenance doses based solely on an online symptom list.

Conclusion

Successful CAH treatment is a continuing balancing process. Undertreatment may cause cortisol deficiency, adrenal crisis, androgen excess, rapid childhood growth, advanced bone age, menstrual problems, or impaired fertility. Overtreatment may cause poor height growth, weight gain, high blood pressure, Cushingoid changes, metabolic complications, and weakened bones.

The safest approach combines consistent medication use, an individualized sick-day plan, emergency preparedness, physical examinations, growth and blood pressure tracking, and laboratory tests collected at consistent times. The goal is not to produce the prettiest isolated hormone result. It is to help the person grow, develop, and live well while minimizing risks on both sides of the treatment equation.